Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139008 · ClinicalTrials.gov registry record · Phase 4
Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT01139008 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 80 participants.
The verdict
NCT01139008, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
Interventions
- DRUG metronidazole 1% gel
- DRUG azelaic acid 15% gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139008
The ClinicalTrials.gov registry entry for NCT01139008 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which metronidazole 1% gel is the first listed.
NCT01139008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139008 about?
NCT01139008 is a clinical study titled "Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin". The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
What is the current status of trial NCT01139008?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2010-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01139008?
The interventions under investigation include: metronidazole 1% gel (DRUG), azelaic acid 15% gel (DRUG).
Who is sponsoring clinical trial NCT01139008?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.